Skip to main content
Predicting developmental outcomes in preterm infants: A simple white matter injury imaging rule.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.
Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I.
Mind the gap: Quantifying gender representation as a first step to solve the problem?
Body mass index, but not vitamin D status, is associated with brain volume change in MS.
Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
Socioeconomic determinants of outcome after childhood arterial ischemic stroke.
Telemedicine in a pediatric headache clinic: A prospective survey.
Ovarian aging is associated with gray matter volume and disability in women with MS.